A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Clinical trial NCT05585632 · COMPLETED

Trial details

NCT number: NCT05585632
Sponsor: ModernaTX, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

SARS-CoV-2 Influenza RSV

Start date: 2022-10-14
Primary completion: 2024-02-28
Enrollment: 392

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.